ELEV vs. LYEL, ACRV, CHRS, ADCT, VXRT, NKTX, PLX, GLSI, DRUG, and ACTU
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Lyell Immunopharma (LYEL), Acrivon Therapeutics (ACRV), Coherus BioSciences (CHRS), ADC Therapeutics (ADCT), Vaxart (VXRT), Nkarta (NKTX), Protalix BioTherapeutics (PLX), Greenwich LifeSciences (GLSI), Bright Minds Biosciences (DRUG), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.
Elevation Oncology vs.
Elevation Oncology (NASDAQ:ELEV) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
In the previous week, Elevation Oncology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for Elevation Oncology and 1 mentions for Lyell Immunopharma. Elevation Oncology's average media sentiment score of 0.41 beat Lyell Immunopharma's score of -0.13 indicating that Elevation Oncology is being referred to more favorably in the media.
Elevation Oncology has higher earnings, but lower revenue than Lyell Immunopharma. Elevation Oncology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Elevation Oncology received 21 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 76.09% of users gave Elevation Oncology an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
Elevation Oncology currently has a consensus price target of $7.20, indicating a potential upside of 912.23%. Lyell Immunopharma has a consensus price target of $1.00, indicating a potential upside of 73.76%. Given Elevation Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe Elevation Oncology is more favorable than Lyell Immunopharma.
Elevation Oncology has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Elevation Oncology's return on equity.
Elevation Oncology has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500.
Summary
Elevation Oncology beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:ELEV) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ELEV Stock Alerts